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Abstract
CD8+ cells from healthy, asymptomatic HIV-1-infected individuals can inhibit HIV-1 replication in naturally or acutely infected CD4+ cells in
the absence of cell killing. This CD8+ cell noncytotoxic anti-HIV response (CNAR) is mediated by a soluble CD8+ cell antiviral factor (CAF).
CNAR/CAF inhibits HIV-1 replication by blocking viral RNA transcription. HIV transcription is regulated by a variety of cis-acting DNA
sequence elements within the proviral long terminal repeat (LTR). We hypothesized that one of the HIV-1 LTR proviral DNA sequence elements
that binds host cell transcriptional factors is involved in this antiviral activity. To assess this possibility, we constructed full-length infectious HIV-1
molecular clones with mutations in the LTR elements NFAT, AP-1, IL-2 homology region, and the downstream ISRE. We also tested full-length
infectious molecular clones that had deletions of either the NF-κB or Sp1 sites of the LTR or lacked functional Tat and TAR elements. Viruses
generated from these molecular clones were used to acutely infect CD4+ cells that subsequently were either co-cultured with CD8+ cells from
individuals that exhibited strong CNAR or cultured with CAF-containing fluids. The replication of all of the mutant HIV-1 viruses tested was
substantially reduced in the presence of CNAR/CAF. These findings suggest that other regions in the viral LTR or other host cell processes are
involved in the transcriptional block elicited by CNAR/CAF.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV; CD8+ cell antiviral response; Virus replication; LTR mutantsIntroduction
Human immunodeficiency virus type 1 (HIV-1), the
etiological agent of the acquired immunodeficiency syndrome
(AIDS), infects T lymphocytes and macrophages that bear the
CD4 receptor and one or both of the co-receptors, CXCR4 or
CCR5 (Clapham and McKnight, 2001; Weiss, 2002). Following
virus entry into these cells, the single-stranded RNA genome of
HIV-1 is reverse transcribed to double-stranded proviral DNA
that stably integrates into the host cell genome (Acheampong
et al., 2003). Once integrated, transcription of full-length viral⁎ Corresponding author. University of California, San Francisco, Department
of Medicine, Box 1270, San Francisco, CA 94143-1270. Fax: +1 415 476 8365.
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doi:10.1016/j.virol.2007.11.003genomic RNA from the provirus LTR promoter ensues, and
various subgenomic mRNA species are generated from genomic
RNA via differential splicing (Muesing et al., 1985; Peterlin,
1995). The initial phase of HIV-1 proviral gene expression is
controlled by cellular transcription factors that bind to a variety
of cis-acting DNA sequences in the LTR and downstream sites
(Greene and Peterlin, 2002; Pereira et al., 2000; Rohr et al.,
2003). During this phase, a basal level of HIV-1 proviral
transcription occurs, resulting in the expression of the
transactivating protein, Tat. Once expressed, Tat dramatically
enhances HIV-1 transcription initiation, elongation, and pro-
cessivity by interacting with the Tat-responsive transactivation-
responsive region (TAR) of nascent viral RNA transcripts
(Berkhout et al., 1989; Kao and Wilkinson, 1987; Raha et al.,
2005).
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individuals can suppress HIV-1 replication in naturally and
acutely infected CD4+ cells without killing the cells (Levy et al.,
1996;Walker et al., 1991, 1986;Wiviott et al., 1990). This CD8+
cell noncytotoxic anti-HIV response (CNAR) inhibits replica-
tion of HIV-1, HIV-2, and simian immunodeficiency virus
(SIV), in a non-HLA-restricted manner, and likely represents an
innate cellular immune response to viral infection (Levy, 2001;
Levy et al., 1996; Mackewicz et al., 1998). CNAR activity has
been shown to be associated with secretion of a CD8+ cell
antiviral factor, CAF (Levy, 2003; Walker and Levy, 1989).
CNAR/CAF inhibits viral replication in CD4+ cells at the
level of transcription and not early infection steps including
HIV-1 entry, reverse transcription, and integration (Chen et al.,
1993; Copeland et al., 1995; Mackewicz et al., 1995, 2000). In
this study, we used infectious HIV-1 molecular clones with
mutations introduced in the LTR to determine whether
alterations in sequence elements of the HIV-1 LTR and nearby
sites that prevent binding of cellular transcription factors, or
disruption of the Tat/TAR system, could be involved in the
transcriptional block exerted by CNAR and CAF.Fig. 1. (A) Diagrammatic representation of the HIV-1 LTR and downstream sites sho
CNAR. Numbering for the NF-κB sites corresponds to molecular clone pNL4-3, a
compared to the sequence of respective wild-type molecular clones. Underlined base
descriptions of molecular clone HIV-tTA, consult Materials and methods and refereResults
Derivation of HIV-1 variants with mutations in the LTR and
other transcriptional motifs
A diagrammatic representation of the HIV-1 LTR and nearby
sequence elements investigated in this study is given in Fig. 1.
DNA sequences of HIV-1SF33 mutant viruses are shown in
Fig. 1B compared to the wild-type molecular clone (accession
no. AY352275 (York-Higgins et al., 1990)). The virus dl-NF
sequences are indicated compared to the parental virus HIV-1
NL4-3 (HIV-1NL4-3 throughout), accession no. M19921 (Adachi
et al., 1986) and virus dl-Sp sequences are compared to the
parental virus HIV-1ILIC. For the HIV-1SF33 mutant viruses, two
mutations of 3 bp each (AAA to CCC) were introduced to create
pISRE. These mutations interfere with binding of interferon
regulatory factors (IRFs) to the ISRE (Van Lint et al., 1997). The
pPRR virus contains a 10-bpmutation in a region of the LTR that
shares homology with the IL-2 purine-rich response element
(PRRE) (Sikder et al., 1994). Previous studies have shown that
this region of the LTR may act as a transcriptional responsewing cis-acting DNA sequence elements mutated to assess their involvement in
nd Sp1 sites correspond to molecular clone ILIC. (B) Site-directed mutations
s indicate the site of interest, and bold bases denote the introduced mutation. For
nce (Verhoef et al., 2001).
Fig. 2. Replication kinetics of wild-type and mutant viruses used in the CNAR
and CAF assays. (A) Replication kinetics of viruses generated from the HIV-
1SF33 wild-type and mutant molecular clones. (B) Replication kinetics of virus
derived from the pNL4-3 wild-type molecular clone, the NF-κB-deficient
molecular clone dl-NF, and the Tat/TAR mutant HIV-tTA. Virus replication
studies were performed using primary human CD4+ T cells. Cell-free
supernatants of wild-type and mutant viruses propagated in primary human
PBMC were used to inoculate CD4+ T cells with equivalent TCID50 doses.
Production of progeny virions was monitored by RT assay (Hoffman et al.,
1985). Results are representative of 2–3 separate studies.
32 K.R. Bonneau et al. / Virology 373 (2008) 30–38element for T cell activation (Markovitz et al., 1992). Mutant
viruses pAP-1.1 and pAP-1.2 were constructed by changing T in
the AP-1 consensus sequence to either G or C (Li et al., 1994).
Virus pAP-1.1 hasmutations in the first and second (5′ to 3′) AP-1
sites, and pAP-1.2 in the third AP-1 site. Virus pNFAT was
created by introducing a 10-bp mutation in the NFAT binding site
of the IL-2 homology region, downstream of the mutation present
in pPRR. This mutation interferes with NFAT binding (Markovitz
et al., 1992).
The deletion mutation present in dl-NF completely removed
both NF-κB sites from the parental molecular clone, pNL4-3
(Leonard et al., 1989) while the deletion present in dl-Sp
completely removed all three Sp1 sites from molecular clone
pILIC (Leonard et al., 1989; Parrott et al., 1991). The HIV-tTA
molecular clone (not shown) is a derivative of the HIV-1LAI
proviral molecular clone, and harbors mutations in both the
TAR region of the LTR and the 5′ region of the tat gene, and is
similar to the previously described doxycyline-regulated HIV-
rtTAmolecular clone (Das et al., 2005; Verhoef et al., 2001) (see
Materials and methods). All mutations were confirmed by DNA
sequencing of both the mutagenized molecular clones and the
progeny virus after 10 to 14 days in culture to ensure mutant
viruses did not revert to wild type (see Materials and methods).
Replication kinetics of viruses
Equivalent amounts (TCID50) of wild-type and mutant virus
stocks were used to infect primary human CD4+ cells to assess
the kinetics and extent of replication of each virus used in this
study. Results are representative of at least two separate studies
(Fig. 2). HIV-1SF33 mutant viruses pISRE, pPRR, pAP-1.1,
pAP-1.2, and pNFAT exhibited delayed replication kinetics
compared to the wild-type virus (Fig. 2A). The amount of virus
produced from cells infected with pPRR and pAP-1.2 was
substantially lower than wild-type HIV-1SF33, suggesting a
reduced replication fitness in CD4+ cells. Viruses pAP-1.1 and
pNFAT reached peak levels of virus production on day 9 which
were comparable to levels of HIV-1SF33 observed on day 4. The
replication kinetics of viruses HIV-1NL4-3, dl-NF, and HIV-tTA
are shown in Fig. 2B. The NF-κB deletion mutant dl-NF
displayed replication kinetics similar to parental wild-type virus
HIV-1NL4-3. HIV-tTA exhibited replication kinetics similar to the
two aforementioned viruses, reaching high levels of replication
on day 7 post-inoculation that gradually increased until day 14.
Progeny production by dl-NF and HIV-tTA resembled that of
HIV-1NL4-3 (data not shown). The dl-Sp virus showed replica-
tion kinetics similar to that of the wild-type virus, HIV-1ILIC but
had 7- to 10-fold lower virus production; peak virus replication
occurred at day 10 (data not shown). In all cases, as observed
with the wild-type viruses, mutant viruses caused cytopathic
effects in CD4+ cells, with syncytia induction and eventual
widespread cell death.
Suppression of parental virus replication by CNAR
Activated CD8+ cells from ten HIV-1-infected subjects,
previously shown to exhibit strong CNAR, and 14 HIV-seronegative subjects who lacked CNAR, were used to evaluate
the dependence of this anti-HIV activity on various LTR
sequences (Table 1). First, the CD8+ cells from several HIV-1-
infected subjects were tested for their ability to inhibit
replication of wild-type virus HIV-1SF33. Cells from all these
individuals efficiently suppressed the virus as indicated by
N90% inhibition of RT activity at the 2:1 CD8+:CD4+ cell input
ratio (Table 1). At a 1:1 ratio, CD8+ cells from 5 out of 9 of the
subjects suppressed virus replication by ≥90%; the other 4
showed ≥78% inhibition. On average, the 2:1, 1:1, and 0.5:1
CD8+:CD4+ cell input ratios of the subject panel suppressed
HIV-1SF33 replication by 96.9, 87.4, and 68.4%, respectively
(n=9; HIV-positive subject panel, Table 1). In contrast, CD8+
cells from all the HIV-seronegative control subjects failed to
suppress replication of HIV-1SF33 at any CD8
+:CD4+ cell input
ratio tested, and many showed enhancement of HIV-1SF33
replication (−26.7 and −17.2% at the 1:1 and 0.5:1 CD8+:CD4+
cell input ratios, respectively).
HIV-1NL4-3 replication in acutely infected CD4
+ cells was
also strongly suppressed at all the CD8+:CD4+ cell input ratios
using CD8+ cells from six HIV-1-infected subjects (Table 1,
Fig. 3) and HIV-1ILIC replication was inhibited by CD8
+ cells
Table 1
Percent suppression of virus replication in CD8+ cell:CD4+ cell co-cultures and by CAF-containing fluids
Virus CD8+:CD4+
cell ratio
Subject CAF fluid
1 2 3 4 5 6 7 8 9 10 NL a A B C D
HIV-1SF33
b 2:1 99.1 98.8 94.9 98.2 98.4 95.8 99.9 91.3 95.4 – – c
1:1 94.9 82.7 92.3 93.4 85.0 78.3 99.8 77.7 90.0 – −26.7 d, e 74.2 62.4 66.9 –
0.5:1 66.5 32.6 57.0 96.6 66.3 70.7 98.9 41.5 77.8 – −17.2
NL4-3 b 2:1 99.9 99.9 – – 99.3 99.9 99.9 99.5 – – –
1:1 99.9 99.8 – – 99.5 99.5 99.9 98.6 – – 29.7 – 54.0 – –
0.5:1 99.9 98.8 – – 88.0 94.1 99.9 94.3 – – 22.3
ILIC b 2:1 – – – – – – – – – 99.9 f –
1:1 – – – – – – – – – 99.9 f 36.6 – – – 57.2 f
0.5:1 – – – – – – – – – 96.0 f 20.3
pISRE 2:1 88.1 99.2 99.4 99.3 99.0 99.6 – – – – –
1:1 88.0 98.9 98.8 99.1 98.2 98.7 – – – – 27.2 59.0 – – –
0:5:1 87.8 99.0 97.3 98.8 89.2 94.3 – – – – −43.7
pPRR 2:1 – 98.7 – 96.7 94.3 99.1 – – – – –
1:1 – 99.8 – 95.2 94.1 98.9 – – – – 56.4 97.6 – – –
0.5:1 – 99.8 – 95.8 93.0 99.4 – – – – −13.8
pNFAT 2:1 99.8 99.8 – – – 99.8 99.8 – – – –
1:1 99.8 99.0 – – – 99.4 99.8 – – – 59.2 g – – 85.6 –
0:5:1 99.7 97.9 – – – 97.2 99.8 – – – 29.1 g
pAP-1.1 2:1 91.6 – – 97.4 88.8 99.5 – 95.8 – – –
1:1 89.3 99.8 – 96.9 86.8 99.8 – 77.4 – – 31.5 – 58.2 – –
0.5:1 71.5 – – – 81.2 99.5 – – – – 20.8
pAP-1.2 2:1 99.7 94.6 – – 99.6 99.5 99.9 – – – –
1:1 99.0 91.5 – – 99.3 94.8 99.8 – – – 9.7 68.3 – – –
0.5:1 94.4 78.3 – – 85.8 92.2 99.6 – – – −16.7
dl-NF 2:1 92.6 98.7 – – – – 99.5 98.0 – – –
1:1 69.9 89.5 – – – – 99.7 93.5 – – 22.0 69.1 – – –
0.5:1 – 64.0 – – – – 99.7 91.0 – – 3.0
dl-Sp 2:1 – – – – – – – – – 99.9 f –
1:1 – – – – – – – – – 99.9 f 72.6 – – – 64.9 f
0.5:1 – – – – – – – – – 99.0 f 68.2
Tat/TAR (HIV-tTA) 2:1 – 99.5 – – 99.7 – 99.8 – 99.6 – –
1:1 – 99.2 – – 99.5 – 99.8 – 99.6 – −1.5 – 63.7 – –
0.5:1 – 95.0 – – 96.2 – 99.7 – 99.6 – −73.8
CAF, CD8+ cell antiviral factor.
a NL represents results with HIV-1-seronegative subject(s).
b Wild-type virus.
c Not done.
d Negative values represent enhancement of virus replication.
e Average of fourteen CD8+ cell:CD4+ cell co-culture assays.
f Representative of studies with three different subjects or fluids.
g Average of six CD8+ cell:CD4+ cell co-culture assays.
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one subject are shown). The CD8+ cells from the HIV-
seronegative control subjects used did not appreciably suppress
replication of these two parental HIV-1 isolates (Table 1).
Suppression of mutant virus replication by CNAR
CD8+ cells from HIV-1-infected subjects also suppressed
replication of all the mutant viruses derived from HIV-1SF33(Table 1). The CD8+ cells from 4–6 HIV-infected subjects
evaluated inhibited by ≥88% the replication of mutant viruses
pISRE, pPRR and pNFAT at all CD8+:CD4+ cell input ratios
(Table 1, Fig. 3). CD8+ cells from all HIV-infected subjects
tested also controlled the replication of viruses pAP-1.1 and
pAP-1.2 by≥85% at the 2:1 CD8+:CD4+ cell input ratio and in
most cases at the 1:1 and 0.5:1 cell input ratios.
CD8+ cells from HIV-seronegative subjects failed to
appreciably suppress replication of most of the mutant viruses
Fig. 3. Graphical representation of percent suppression of virus replication by
CD8+ cells from HIV-infected individuals. Open circles, 1:1 CD8+:CD4+ cell
input ratio; black circles, 0.5:1 CD8+:CD4+ cell input ratio. Data were subjected
to paired t-tests (two-tailed) to compare mutant viruses to their respective
parental viruses. The tat/TAR mutant HIV-tTAwas compared to both HIV-1SF33
and HIV-1NL4-3. Asterisks indicate those mutant viruses that showed a
significant difference in sensitivity to CD8+ cell suppression of virus replication
when compared to the parental virus ( p≤0.05). Figure provided by S. Killian.
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+ cells from HIV-
seronegative control subjects showed moderate suppression of
virus pPRR replication at the 1:1 CD8+:CD4+ cell ratio (56.4%)
and some suppression of pNFAT virus replication (an average of
59.2% and 29.1% at the 1:1 and 0.5:1 CD8+:CD4+ cell input
ratios, respectively).
CD8+ cells from all the HIV-infected subjects tested sub-
stantially suppressed as well the production of the HIV-1NL4-3
and HIV-1ILIC-derived mutant viruses dl-NF and dl-Sp (Table 1;
dl-Sp results with one subject's CD8+ cells are shown). The
CD8+ cells from HIV-seronegative control subjects did not
suppress dl-NF but moderately inhibited replication of dl-Sp
(Table 1). To determine if Tat or TAR was involved in CNAR,
the HIV-tTA mutant virus was evaluated. Its replication was
blocked in the presence of CNAR associated with CD8+ cells
obtained from the four HIV-infected subjects studied. CD8+
cells from the HIV-seronegative subject were unable to control
replication of this virus.
Statistical analysis of CNAR results
A comparison of the ability of CD8+ cells to suppress the
parental vs. mutant viruses revealed no significant difference in
inhibition of virus replication by CD8+ cells from HIV-infected
subjects except for mutant viruses pISRE and pAP-1.2 (Fig. 3).
These viruses were found to be more susceptible to CNAR than
HIV-1SF33 (Fig. 3; p=0.021 at 0.5:1 CD8
+:CD4+ cell input ratio
for pISRE, and p=0.034 and 0.047 at 0.5:1 and 1:1 CD8+:CD4+
cell input ratios, respectively, for pAP-1.2). In addition, CD8+
cells from HIV seronegative subjects compared to those from
HIV-infected subjects showed no significant ability to suppress
replication of any of the viruses except for dl-Sp. This virus was
suppressed by CD8+ cells from HIV seronegative individuals by
73% at a 1:1 CD8+:CD4+ cell input ratio which was notstatistically different than the results with CD8+ cells from the
HIV-infected subjects (p=0.594). Moreover, at the low CD8+:
CD4+ cell input ratios tested, dl-Sp was significantly more
sensitive to suppression by CD8+ cells from the HIV-uninfected
individuals than was the parental virus, HIV-1ILIC (p=0.034 and
0.035 at the 0.5:1 and 1:1 CD8+:CD4+ cell input ratios,
respectively). Mutant viruses pNFAT and pPRR that were
moderately suppressed by CD8+ cells from HIV-seronegative
subjects at the 1:1 CD8+:CD4+ cell input ratio (59.2% and
56.4%, respectively), were also statistically more sensitive to
these cells than the parental HIV-1SF33 virus (p=0.02 and 0.01
for pNFAT and pPRR, respectively).
Comparison of mutant virus HIV-tTA to HIV-1SF33 or HIV-
1NL4-3 showed no statistically significant difference in suppres-
sion of virus replication by CD8+ cells from HIV-infected
subjects (Fig. 3; p=0.110 and 0.070 at the 0.5:1 and 1:1 CD8+:
CD4+ cell input ratios, respectively vs. HIV-1SF33, and p=0.732
and 0.336 at the 0.5:1 and 1:1 CD8+:CD4+ cell input ratios,
respectively vs. HIV-1NL4-3).
Suppression of mutant HIV viruses by CAF
To assess the effect of the soluble anti-HIV factor, CAF, on
the replication of the mutant viruses, CAF-containing fluids
were evaluated. The CAF fluids used in the study were able to
suppress the wild-type parental viruses, HIV-1SF33, HIV-1NL4-3,
and HIV-1ILIC by N50%, as has been observed with CAF activity
(Mackewicz et al., 1994). Reduction in mutant virus replication
ranged from 58.2% (pAP-1.1) to 97.6% (pPRR) in CD4+ cells
acutely infected with mutant viruses and maintained in medium
containing 50% CAF fluid (Table 1). Thus, fluids that showed
CAF activity against wild-type viruses suppressed the replication
of all viruses evaluated. In contrast, CAF-negative fluid from an
HIV-1-seropositive subject that lacked the ability to suppress
wild-type HIV-1SF33 replication failed to suppress the replication
of any of the mutant or parental viruses (data not shown).
Discussion
The CD8+ cell noncytotoxic anti-HIV response (CNAR) has
been shown to block HIV replication at the transcriptional level
(Chen et al., 1993; Mackewicz et al., 1995). This study was
undertaken to determine whether certain transcriptional regulat-
ing domains in the HIV-1 LTR and nearby regions are sensitive
to this antiviral activity. We hypothesized that one or more
transcription factor binding sites of the HIV promoter are
involved in the mediation of virus inhibition by CNAR. To
evaluate this possibility, we derived viruses with mutations in
the HIV-1 LTR or obtained previously described deletion
mutant viruses lacking certain regions of the LTR (Fig. 1).
For these studies, attention was given to cis-acting LTR and
downstream sequences that control basal HIV-1 proviral gene
transcription by interacting with host cell transcription factors.
Among these are the sites ISRE, IL-2 homology region, NFAT,
AP-1, NF-κB, and Sp1 (Battistini et al., 2002; Pereira et al.,
2000). Mutations targeted to the aforementioned sites prevent
interaction with their cognate DNA binding proteins and can
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replication (Jones et al., 1986; Leonard et al., 1989; Li et al.,
1994; Liang et al., 1997; Lu et al., 1990; Markovitz et al., 1992;
Mouzaki et al., 2000; Tong-Starksen et al., 1987; Van Lint et al.,
1997; Wu et al., 1988).
Importantly, our results indicated that several transcription
factor binding sites of the viral LTR and nearby regions are not
required for virus replication (Figs. 2A and B). However, some
reduction in virus production was noted for HIV-1SF33 mutants
with altered ISRE, IL-2 homology region (PRR), AP-1, and
NFAT site(s). Mutations in these sites resulted in progeny virus
with delayed replication kinetics, and lower virus progeny
yields (in most cases) compared to wild-type HIV-1SF33.
Moreover, the NF-κB and Sp1 deletion mutants, as well as
the Tat/TAR deleted mutant, had lower viral progeny production
than the wild-type viruses. Nevertheless, all the deletion
mutants showed substantial virus replication in CD4+ T cells
(Fig. 2).
Notably, the results indicated that all of the infectious mutant
viruses studied were sensitive to CNAR and CAF-containing
fluids. This finding demonstrates that the CD8+ cell-mediated
transcriptional block may not individually involve the ISRE, IL-
2 homology region, NFAT, AP-1, NF-κB, or Sp1 sites that drive
HIV-1 proviral transcription, nor require a Tat/TAR interaction.
However, these observations do not preclude the possibility that
two or more sites may be associated with the suppression of
HIV-1 replication mediated by CNAR/CAF.
Previous studies suggested that suppression of HIV-1 LTR-
driven transcription by CAF-containing fluids was abolished
when mutations were introduced into the NFAT/IL-2 homology
region of the LTR. In contrast, mutations within the NF-κB site
resulted in no alteration in the ability of CAF-containing super-
natants to inhibit HIV-1 LTR-driven transcription or simian
immunodeficiency virus (SIV) replication in infected cells
(Copeland et al., 1996; Locher et al., 2001). However, the report
showing involvement of the HIV-1 NFAT/IL-2 homology sites
utilized an LTR reporter construct directing chloramphenicol
acetyltransferase expression in the established Jurkat T cell line
(Copeland et al., 1996). Our studies, which indicate strong
suppression of mutant viruses pPRR (IL-2 homology region)
and pNFAT by CNAR and CAF, utilized the more biologically
relevant system of virus replication in primary CD4+ cells. The
findings indicate that the IL-2 homology region and NFAT are
not required for the transcriptional block elicited by CNAR/
CAF (Table 1, Fig. 3).
It is noteworthy that the LTR mutations present in viruses
pISRE, pPRR, pNFAT, pAP-1.2, and particularly dl-Sp,
rendered these viruses somewhat more susceptible to CD8+
cell suppression when measured at the 1:1 and 0.5:1 CD8+:
CD4+ cell input ratios (Table 1, Fig. 3). The results with pISRE,
and pAP-1.2 were significant when these mutant viruses were
compared to the parental virus (HIV-1SF33) in CNAR assays
utilizing CD8+ cells from HIV-infected individuals. When
results with CD8+ cells from HIV-uninfected subjects were
compared to those with CD8+ cells from HIV-positive subjects,
only dl-Sp showed a similar sensitivity to virus suppression.
Moreover, CD8+ cells from the HIV-uninfected individualsevaluated statistically inhibited dl-Sp in comparison to the
parental virus, HIV-1ILIC, and significantly suppressed replica-
tion of the pPRR and pNFAT mutant viruses in comparison to
HIV-1SF33 at the 1:1 CD8
+:CD4+ cell input ratio (Table 1,
Fig. 3). Activated CD8+ cells from some uninfected subjects
can show CNAR activity against wild-type viruses but generally
at higher cell input ratios (Mackewicz and Levy, 1992). The
reason for the current findings with CD8+ cells from uninfected
subjects is not known but could be due to the reduced repli-
cation capacity of these particular mutant viruses (Fig. 2).
Other mechanisms regulating transcription may be targeted
by CNAR, or two or more cis-regulatory elements could be
involved in CNAR/CAF, and several must be mutated before
inhibition of replication by CNAR/CAF can be overcome.
Alternatively, the mechanism in CD4+ cells resulting in a block
of HIV-1 replication elicited by CNAR may not directly involve
the HIV-1 LTR. These possibilities are being explored, as well
as the effect of additional viral and host cell processes on
CNAR/CAF activity.
Materials and methods
Subjects
Peripheral blood buffy coats from uninfected subjects were
provided by the Blood Centers of the Pacific (San Francisco,
CA). Heparinized peripheral blood samples were obtained by
venipuncture from clinically healthy, HIV-1-seropositive sub-
jects belonging to the laboratory cohort at the University of
California, San Francisco (UCSF). The Committee for Human
Research at UCSF approved this study, and all participants
signed an informed consent form prior to the study.
Isolation of cell subsets
Peripheral blood mononuclear cells (PBMC) were obtained
from the blood of uninfected and HIV-1-infected subjects by
Ficoll-Hypaque (Sigma-Aldrich, St. Louis, MO) gradient
centrifugation. The cells were stimulated with phytohemagglu-
tinin (PHA) (3 μg/ml; Sigma-Aldrich, St. Louis, MO) for 3 days
in RPMI 1640 culture medium containing 10% heat-inactivated
(56 °C, 30 min) fetal bovine serum supplemented with 10%
natural IL-2 (20 U/ml; Roche, Indianapolis, IN), 2 mM L-
glutamine, 100 μg/ml streptomycin, and 100 U/ml penicillin
(BioWhittaker [now Cambrex, Rockland, ME]) (Castro et al.,
1988). CD4+ and CD8+ cells from seronegative and HIV-1-
seropositive subjects, respectively, were obtained from the
activated PBMC by positive selection using immunomagnetic
(IM) beads bearing anti-CD4 or anti-CD8 mAbs (Miltenyi
Biotec, Auburn, CA). Purity of the cell subset population was
assessed by flow cytometry (Levy et al., 1985) by which N97%
of the cells were found to be CD4+ or CD8+.
Generation and propagation of mutant viruses
Site-directed mutagenesis was used to individually mutagenize
the IL-2 homology region, ISRE, NFAT, and AP-1 sites of the
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Mutations were introduced using the QuikChange II XL Site-
DirectedMutagenesis Kit (Stratagene). A total of fivemutant virus
clones were produced: pISRE, pPRR, pNFAT, pAP-1.1, and pAP-
1-2. Mutations were introduced in both the 5′ and 3′ LTR of the
HIV-1SF33molecular clone (York-Higgins et al., 1990) to eliminate
the possibility of reversion to wild-type virus by recombination,
with the exception of pISRE, the single-targeted site of which lies
downstream of the LTR. The mutant molecular clones were
constructed using the following primer pairs: pISRE forward
5′-GCCCGAACAGGGACTTGCCCGTGCCCGTTAACCA-
GAGGAGCTC-3′ and reverse 5′-GAGCTCCTCTGGTTAAC-
GGGCACGGGCAAGTCCCTGTTCGGGC-3′; pPRR forward
5′-AGGCCAATGCCAAGCTTCGCAACAGCTTGTTACACC-
CTATGAGCC-3′ and reverse 5′-GGCTCATAGGGTGTAA-
CAAGCTGTTGCGAAGCTTGGCATTGGCCT-3′; pNFAT
forward 5′-CCAATGAAGGAGAGAACAACACTCGAGG-
CACCCCTATGAGCCTGC-3′ and reverse 5′-GCAGGCTCA-
TAGGGGTGCCTCGAGTGTTGTTCTCTCCTTCATTGG-3′;
pAP-1.1 forward 5′-CCAGGGCCAGGCGTCGGATTTC-
CGCTGGCCTTTGGATG-3′ and reverse 5′-CATCCAAAGGC-
CAGCGGAAATCCGACGCCTGGCCCTGG-3′; pAP-1.2
forward 5′-GTTAGTACCAGTAGCGCCGGAGAAAGTA-
GAAGAGGCC-3′ and reverse 5′-GGCCTCTTCTACTTTC-
TCCGGCGCTACTGGTACTAAC-3′. Underlined bases indicate
mutations.
Following mutagenesis, mutations were confirmed in
molecular clones by automated DNA sequencing (UCSF,
Biomolecular Resource Center), and clones harboring the
desired mutations were transfected into 293 cells using the
FuGene 6 transfection reagent following the manufacturer's
protocol (Roche). Twenty-four hours post-transfection, 8×106
IM-bead-purified, 3-day PHA-stimulated CD4+ cells from
uninfected subjects in 4 ml of culture medium were added to
the transfected 293 cells, and co-cultured at 37°C, 5% CO2 for 2
or 3 days. The CD4+ cells were then transferred to separate
flasks, cultured for 10–14 days with fresh culture medium and
PBMC added every 4 days. Culture fluids were monitored for
virus production using the particle-associated reverse transcrip-
tase (RT) activity assay (Hoffman et al., 1985). Once RTactivity
reached ≥300,000 counts per minute/ml (cpm/ml), the virus
was used to infect freshly isolated, 3-day stimulated PBMC, and
the infectious mutant viruses were propagated and titered (i.e.,
TCID50) as previously described (McDougal et al., 1985).
The NF-κB and Sp1 deletion mutant viruses dl-NF and dl-
Sp were propagated from the previously described molecular
clones (Leonard et al., 1989; Parrott et al., 1991); the parental
viruses HIV-1NL4-3 and HIV-1ILIC were generated from their
respective molecular clones, pNL4-3 and pILIC (Adachi et al.,
1986). The pNL4-3 clone was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, and was provided by Malcolm Martin. The Tat/
TAR mutant virus (HIV-tTA), which is a variant of the dox-
dependent HIV-rtTA virus (Verhoef et al., 2001) with the
reverse dox control, was propagated from the proviral molec-
ular clone in the absence of doxycycline. This mutant virus was
generated from the infectious HIV-1 molecular clone pLAI bymutating the TAR viral transcription element, introducing
tetracycline operator (tetO) sequences into the LTR, replacing
the nef gene with tetracycline-controlled transactivator (tTA),
and inactivating the tat gene by point mutation. Hence, this
molecular clone is identical to HIV-rtTA described by Verhoef
et. al., with the exception that the tTA transcriptional activator
was used instead of rtTA in replacing the nef gene (Verhoef
et al., 2001). Progeny viruses were replication-competent in
the absence of doxycycline (Fig. 2B) despite lacking a
functional Tat/TAR axis of transcription regulation (Gossen
and Bujard, 1992).
Mutations were confirmed in all progeny virus RNA after 10
to 14 days in CD4+ cell culture by RT-PCR amplification of
select LTR regions followed by automated sequencing analysis
(data not shown), in order to ensure mutant viruses did not revert
to wild type. Infectious viruses were confirmed to have the
desired mutations andwere used in the acute assay for measuring
CNAR and CAF activity.
Virus replication kinetics
Replication kinetics and extent of virus production by
parental and mutant viruses were evaluated by infecting PHA-
stimulated CD4+ cells with approximately 104 TCID50 of virus
per 106 cells as described above. Cells were plated at 106 cells
per well in 24-well plates, in 1.5 ml of RPMI 1640 culture
medium containing 10% IL-2 as described above. Fluids (1 ml)
were collected at 2, 4, 7, 9, 11, 14, and 17 days post-inoculation,
and virus replication assessed using the RT assay. Culture
medium (0.25 ml) was added to all remaining wells at day 9
post-inoculation to counter fluid evaporation. Experiments were
performed 2–3 times and representative results are given.
Acute assay for CD8+ cell noncytotoxic anti-HIV response
Acute virus suppression assays were conducted as previously
described (Mackewicz et al., 1991). Briefly, IM bead-purified
CD4+ cells from seronegative donors were PHA-stimulated for
3 days and 107 cells were acutely infected with approximately
104 TCID50 of either the parental or mutant viruses described
above. After 1 h, cells were washed and cultured in 24-well
plates at 0.5×106 cells per well, in 1.5 ml RPMI 1640 culture
medium containing 100 U/ml recombinant IL-2 (provided by
GlaxoWellcome, Research Triangle Park, NC), either alone or in
the presence of CD8+ cells from HIV-1-seropositive or
seronegative subjects at a CD8+ cell:CD4+ cell (CD8+:CD4+
cell) input ratio of 0.5:1, 1:1, and 2:1 in most cases. At days 4, 7,
and 10 after virus inoculation, the cultures were passed and
fluids (1 ml) were collected to measure virus production by the
RT assay (Hoffman et al., 1985). All acute infection assays were
performed in triplicate, and the results were averaged. The range
was always within 10%. The percent suppression of HIV at the
peak level of virus replication was determined by comparing the
RT activity of the CD8+:CD4+ cell co-culture with that of the
infected CD4+ cells cultured alone. A decrease in RT activity by
≥50% was considered evidence of CNAR activity. In most
cases, suppression was N90%. CD8+ cells from HIV-
37K.R. Bonneau et al. / Virology 373 (2008) 30–38seronegative subjects, typically one per mutant virus evaluated,
were used in the CNAR assay as a negative control. A statistical
analysis of the suppression data was conducted by which the
percent suppression of each mutant virus was compared to its
respective parent virus using a paired t-test, two-tailed. A p-
value≤0.05 was considered statistically significant. This
analysis was also used to compare suppression of each virus
by CD8+ cells from HIV-seropositive and -seronegative
subjects, and comparison of suppression of respective parental
and mutant viruses by HIV-seronegative subjects.
Assay for CAF-mediated antiviral activity
CAF-containing fluids were prepared and tested for anti-HIV
activity as previously described (Mackewicz et al., 1994), with
the exception that HIV-1SF33 was used to infect the target CD4
+
cells. A decrease in RT activity by ≥50% was considered
evidence of CAF activity. Briefly, for the CAF assay, 104
TCID50 of wild-type or mutant viruses were used per 10
6 PHA-
stimulated CD4+ cells obtained from HIV-seronegative sub-
jects. After 1-h incubation, cells were washed and plated in
triplicate at 105 inoculated CD4+ cells per well in 96-well plates
in RPMI 1640 culture medium supplemented with 100 U/ml
recombinant IL-2 (Glaxo Wellcome). Acutely infected CD4+
cells were cultured in the presence of CD8+ cell culture fluid
containing or lacking CAF activity diluted 50% with culture
medium, in a final volume of 200 μl. Cultures were passed
every 2 days and monitored for RT activity by removing 100 μl
of culture fluid for the RT activity assay. An equal volume of
diluted CAF or control fluids was added back to the wells at
each passage. The extent of CAF activity (% suppression of
HIV replication) was determined by comparing the RT activity
of the infected CD4+ cells cultured in CAF fluids with that of
the infected CD4+ cells cultured in control medium.
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